The association between atrial natriuretic peptide （ANP） polymorphism and coronary heart disease （CHD） was studied in Chinese population. The genotypes of ANP T2238C and ANP C-664G were detected by polymerase chai...The association between atrial natriuretic peptide （ANP） polymorphism and coronary heart disease （CHD） was studied in Chinese population. The genotypes of ANP T2238C and ANP C-664G were detected by polymerase chain reaction and restriction fragment length polymorphism （PCR-RFLP） methods in 158 consecutive CHD patients and 165 controls. It was found that the distribution of A2A2 genotype in CHD group was significantly higher than that in control group （P〈0.05）. Stepwise Logistic regression analysis revealed that male, smoking, history of hypertension, history of diabetes, family history of hypertension, high level of serum cholesterol, and ANP T2238C polymorphism were the possible risk factors in patients with CHD （P〈0.05）. However, there was no significant difference between the patients with CHD and the control group in the distribution of ANP C-664G polymorphism （P〉0.05）. The results suggest that A2A2 T2238C genotype could be one of the risk factors for CHD （P〈0.05, OR： 1.80, 95 % CI： 1.03-3.15）.展开更多
基金This project was supported by a grant from National Natural Sciences Foundation of China (No.30128021).
文摘The association between atrial natriuretic peptide （ANP） polymorphism and coronary heart disease （CHD） was studied in Chinese population. The genotypes of ANP T2238C and ANP C-664G were detected by polymerase chain reaction and restriction fragment length polymorphism （PCR-RFLP） methods in 158 consecutive CHD patients and 165 controls. It was found that the distribution of A2A2 genotype in CHD group was significantly higher than that in control group （P〈0.05）. Stepwise Logistic regression analysis revealed that male, smoking, history of hypertension, history of diabetes, family history of hypertension, high level of serum cholesterol, and ANP T2238C polymorphism were the possible risk factors in patients with CHD （P〈0.05）. However, there was no significant difference between the patients with CHD and the control group in the distribution of ANP C-664G polymorphism （P〉0.05）. The results suggest that A2A2 T2238C genotype could be one of the risk factors for CHD （P〈0.05, OR： 1.80, 95 % CI： 1.03-3.15）.
